Search
Spesolimab
go.drugbank.com/drugs/DB15626ApprovedInvestigationalin December 2022 for the treatment of flares in adult patients with generalized pustular psoriasis. … Spesolimab is an interleukin-36 (IL-36) receptor antagonist.
Nurulimab
go.drugbank.com/drugs/DB18946InvestigationalNurulimab is under investigation in clinical trial NCT05732805 (A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-pd-1 Compared to Anti-pd-1 Monotherapy as First-line Treatment in
Mitapivat
go.drugbank.com/drugs/DB16236ApprovedInvestigational[A245478] On January 5, 2026, the FDA also approved the use of in the treatment of anemia in adults with alpha- or beta-thalassemia, making it the first oral treatment for this condition.[L54953] … Mitapivat is a novel, first-in-class pyruvate kinase activator. It works to increase the activity of erythrocyte pyruvate kinase, a key enzyme involved in the survival of red blood cells.
Synonyms: Pkr-in-1Vatalanib
go.drugbank.com/drugs/DB04879InvestigationalVatalanib (PTK787/ZK-222584) is a new oral antiangiogenic molecule that inhibits all known vascular endothelial growth factor receptors. Vatalanib is under investigation for the treatment of solid tumors.
Equine Botulinum Neurotoxin G Immune FAB2
go.drugbank.com/drugs/DB13899ApprovedIt is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes G in adults and pediatric patients.
Equine Botulinum Neurotoxin D Immune FAB2
go.drugbank.com/drugs/DB13902ApprovedIt is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes D in adults and pediatric patients. … Equine Botulinum Neurotoxin D Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype D.
Synonyms: Botulinum Neurotoxin D immune FAB2 (equine), BOTULINUM NEUROTOXIN D IMMUNE FAB2, EQUINEOmidubicel
go.drugbank.com/drugs/DB17132ApprovedInvestigational[A258938,A258943,L46048] This type of cell therapy benefits patients that require stem cell transplantation as a treatment for blood cancers for whom a related or unrelated donor cannot be found due to … In addition, the fact that 39% of the study's cohort were non-White patients highlights the importance of this type of treatment in key demographics with low donor availability.
Synonyms: Allogeneic, ex-vivo expanded, umbilical cord blood-derived hematopoietic CD34+ progenitor cells - cultured fraction (CF)Tyrothricin
go.drugbank.com/drugs/DB13503ApprovedWithdrawnNevertheless, as tyrothricin is both cytolytic and hemolytic, it does demonstrate systemic toxicity [L4019, L4021, L4022], although certain formulations that are safe for human use like throat lozenges do … Tyrothricin is an antibiotic peptide complex produced and extracted from the aerobic Gram-positive bacillus Brevibacillus parabrevis [L4019, L4021, A32851] which was previously categorized as Bacillus
Bimekizumab
go.drugbank.com/drugs/DB12917ApprovedInvestigationalBimekizumab is a humanized monoclonal antibody directed towards IL-17, which was approved for use in the EU on August 20, 2021, for the treatment of plaque psoriasis. … Bimekizumab was also granted FDA approval on October 18, 2023.[L48551]
ATG-Fresenius S
go.drugbank.com/drugs/DB05320InvestigationalATG-Fresenius S is a concentrated anti-human T-lymphocyte immunoglobulin preparation derived from rabbits after immunization with a T-lympoblast cell line. … ATG-Fresenius S is an immunosuppressive product for the prevention and treatment of acute rejection following organ transplantation.